Neuropharmacology of mental illness

Paul A. Fredrickson, Elliott Richelson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The interplay of mental illness and sleep is multifaceted. Most psychiatric disorders produce sleep complaints. Behavioral health clinicians routinely inquire about a patient's sleep during diagnostic assessment and to monitor treatment response. Mental illness treatment that does not address sleep problems may lead to relapse. Persistence of insomnia is a negative prognostic sign, particularly for depression. Insomnia is the most common sleep complaint. Chronic insomnia is prevalent in about 10% of the United States' population. Only about one-fifth of these sufferers receive prescription hypnotics. Prescribing practices have changed in recent decades. From 1979 to 1999, survey data showed a decline in traditional hypnotics by 50%. Over that same span, the use of antidepressant drugs to treat insomnia increased more than two-fold [1]. Many people self-medicate for sleep problems. Over-the-counter remedies are primarily antihistaminic agents. Alcohol is also a common remedy, but, for reasons of limited efficacy and abuse potential, its use should be discouraged. Cognitive behavioral therapies, which are outside the scope of this chapter, are an effective alternative for many with chronic insomnia. The focus of this chapter will be on the prescription drugs used to treat psychiatric disorders that either have beneficial or adverse effects on sleep. Some of these drugs are commonly prescribed off-label for insomnia. Others produce insomnia, excessive daytime sleepiness, or parasomnias. Antidepressant therapies Current treatments for depression are largely based on concepts arising from monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) drugs discovered decades ago.

Original languageEnglish (US)
Title of host publicationSleep and Mental Illness
PublisherCambridge University Press
Pages1-6
Number of pages6
Volume9780521110501
ISBN (Print)9781139042734, 9780521110501
DOIs
StatePublished - Jan 1 2010

Fingerprint

Neuropharmacology
Sleep Initiation and Maintenance Disorders
Sleep
Hypnotics and Sedatives
Antidepressive Agents
Psychiatry
Parasomnias
Depression
Monoamine Oxidase Inhibitors
Prescription Drugs
Tricyclic Antidepressive Agents
Cognitive Therapy
Therapeutics
Prescriptions
Alcohols
Recurrence
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fredrickson, P. A., & Richelson, E. (2010). Neuropharmacology of mental illness. In Sleep and Mental Illness (Vol. 9780521110501, pp. 1-6). Cambridge University Press. https://doi.org/10.1017/CBO9781139042734.003

Neuropharmacology of mental illness. / Fredrickson, Paul A.; Richelson, Elliott.

Sleep and Mental Illness. Vol. 9780521110501 Cambridge University Press, 2010. p. 1-6.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fredrickson, PA & Richelson, E 2010, Neuropharmacology of mental illness. in Sleep and Mental Illness. vol. 9780521110501, Cambridge University Press, pp. 1-6. https://doi.org/10.1017/CBO9781139042734.003
Fredrickson PA, Richelson E. Neuropharmacology of mental illness. In Sleep and Mental Illness. Vol. 9780521110501. Cambridge University Press. 2010. p. 1-6 https://doi.org/10.1017/CBO9781139042734.003
Fredrickson, Paul A. ; Richelson, Elliott. / Neuropharmacology of mental illness. Sleep and Mental Illness. Vol. 9780521110501 Cambridge University Press, 2010. pp. 1-6
@inbook{e8b85b383d3342e09bc99bdf37b2cb5e,
title = "Neuropharmacology of mental illness",
abstract = "The interplay of mental illness and sleep is multifaceted. Most psychiatric disorders produce sleep complaints. Behavioral health clinicians routinely inquire about a patient's sleep during diagnostic assessment and to monitor treatment response. Mental illness treatment that does not address sleep problems may lead to relapse. Persistence of insomnia is a negative prognostic sign, particularly for depression. Insomnia is the most common sleep complaint. Chronic insomnia is prevalent in about 10{\%} of the United States' population. Only about one-fifth of these sufferers receive prescription hypnotics. Prescribing practices have changed in recent decades. From 1979 to 1999, survey data showed a decline in traditional hypnotics by 50{\%}. Over that same span, the use of antidepressant drugs to treat insomnia increased more than two-fold [1]. Many people self-medicate for sleep problems. Over-the-counter remedies are primarily antihistaminic agents. Alcohol is also a common remedy, but, for reasons of limited efficacy and abuse potential, its use should be discouraged. Cognitive behavioral therapies, which are outside the scope of this chapter, are an effective alternative for many with chronic insomnia. The focus of this chapter will be on the prescription drugs used to treat psychiatric disorders that either have beneficial or adverse effects on sleep. Some of these drugs are commonly prescribed off-label for insomnia. Others produce insomnia, excessive daytime sleepiness, or parasomnias. Antidepressant therapies Current treatments for depression are largely based on concepts arising from monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) drugs discovered decades ago.",
author = "Fredrickson, {Paul A.} and Elliott Richelson",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9781139042734.003",
language = "English (US)",
isbn = "9781139042734",
volume = "9780521110501",
pages = "1--6",
booktitle = "Sleep and Mental Illness",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Neuropharmacology of mental illness

AU - Fredrickson, Paul A.

AU - Richelson, Elliott

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The interplay of mental illness and sleep is multifaceted. Most psychiatric disorders produce sleep complaints. Behavioral health clinicians routinely inquire about a patient's sleep during diagnostic assessment and to monitor treatment response. Mental illness treatment that does not address sleep problems may lead to relapse. Persistence of insomnia is a negative prognostic sign, particularly for depression. Insomnia is the most common sleep complaint. Chronic insomnia is prevalent in about 10% of the United States' population. Only about one-fifth of these sufferers receive prescription hypnotics. Prescribing practices have changed in recent decades. From 1979 to 1999, survey data showed a decline in traditional hypnotics by 50%. Over that same span, the use of antidepressant drugs to treat insomnia increased more than two-fold [1]. Many people self-medicate for sleep problems. Over-the-counter remedies are primarily antihistaminic agents. Alcohol is also a common remedy, but, for reasons of limited efficacy and abuse potential, its use should be discouraged. Cognitive behavioral therapies, which are outside the scope of this chapter, are an effective alternative for many with chronic insomnia. The focus of this chapter will be on the prescription drugs used to treat psychiatric disorders that either have beneficial or adverse effects on sleep. Some of these drugs are commonly prescribed off-label for insomnia. Others produce insomnia, excessive daytime sleepiness, or parasomnias. Antidepressant therapies Current treatments for depression are largely based on concepts arising from monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) drugs discovered decades ago.

AB - The interplay of mental illness and sleep is multifaceted. Most psychiatric disorders produce sleep complaints. Behavioral health clinicians routinely inquire about a patient's sleep during diagnostic assessment and to monitor treatment response. Mental illness treatment that does not address sleep problems may lead to relapse. Persistence of insomnia is a negative prognostic sign, particularly for depression. Insomnia is the most common sleep complaint. Chronic insomnia is prevalent in about 10% of the United States' population. Only about one-fifth of these sufferers receive prescription hypnotics. Prescribing practices have changed in recent decades. From 1979 to 1999, survey data showed a decline in traditional hypnotics by 50%. Over that same span, the use of antidepressant drugs to treat insomnia increased more than two-fold [1]. Many people self-medicate for sleep problems. Over-the-counter remedies are primarily antihistaminic agents. Alcohol is also a common remedy, but, for reasons of limited efficacy and abuse potential, its use should be discouraged. Cognitive behavioral therapies, which are outside the scope of this chapter, are an effective alternative for many with chronic insomnia. The focus of this chapter will be on the prescription drugs used to treat psychiatric disorders that either have beneficial or adverse effects on sleep. Some of these drugs are commonly prescribed off-label for insomnia. Others produce insomnia, excessive daytime sleepiness, or parasomnias. Antidepressant therapies Current treatments for depression are largely based on concepts arising from monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) drugs discovered decades ago.

UR - http://www.scopus.com/inward/record.url?scp=84926967338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926967338&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139042734.003

DO - 10.1017/CBO9781139042734.003

M3 - Chapter

SN - 9781139042734

SN - 9780521110501

VL - 9780521110501

SP - 1

EP - 6

BT - Sleep and Mental Illness

PB - Cambridge University Press

ER -